| Name | N-Desmethyl Azelastine |
|---|---|
| Synonyms | 2-(azepan-4-yl)-4-[(4-chlorophenyl)methyl]phthalazin-1-one |
| Description | Desmethylazelastine is a main active metabolite of Azelastine that is oxidatively metabolized by the cytochrome P450 enzyme system with a protein binding rate of 97% and an elimination half-life of 54 hours. Azelastine is an orally active, selective and high-affinity histamine H1-receptor antagonist. Azelastine can be used in studies of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2[1][2][3][4][5]. |
|---|---|
| Related Catalog | |
| In Vivo | 1.19Pharmacokinetic parameters of desmethylazelastine after a single oral administration of 1.0 mg/kg azelastine hydrochloride in guinea pigs[1]. Blood Lung Cmax (ng/mL)[a] 17.6 2863 Tmax (h) 3.0-6.0 4.0-6.0 Tlag (h) 0.25 0.39 AUC0-24 (ng•h/mL)[a] 180 28502 t1/2 (h) 4.24 3.90 CL (L/h) 0.213 Lung-blood ratio[b] 146 146[a] For lung, the unit in grams (g) instead of milliliter (mL).[b] Mean value calculated from all time points. |
| References |
| Density | 1.29g/cm3 |
|---|---|
| Boiling Point | 544.1ºC at 760mmHg |
| Molecular Formula | C21H22ClN3O |
| Molecular Weight | 367.87200 |
| Flash Point | 282.8ºC |
| Exact Mass | 367.14500 |
| PSA | 46.92000 |
| LogP | 4.28410 |
| Index of Refraction | 1.66 |
|
~%
47491-38-3 |
| Literature: GLAXO GROUP LIMITED Patent: WO2007/122156 A1, 2007 ; Location in patent: Page/Page column 67 ; WO 2007/122156 A1 |